経皮的冠動脈インターベンションにおけるCYP2C19遺伝子変異とチエノピリジン耐性に関する研究

基本情報

NCT ID

NCT00876512

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

104

治験依頼者名

Kumamoto University

概要

Dual antiplatelet therapy with aspirin and thienopyridines decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. The present study is designed in order to clarify the influence of CYP2C19 genetic polymorphism on the several biomarkers for platelet activation in Japanese patients treated with thienopyridines undergoing elective PCI.

対象疾患

依頼者（Sponsor）

実施施設 (1)